Protective effect of phosphoenolpyruvate carboxykinase 1 on inflammation and fibrotic progression of IgA nephropathy

Ying Tan, Yu–Kai Wang, Xiaomei Luo, Chaoyi Chen, Xue‐qi Liu, Xinran Liu, Yonggui WuRenal 2025 · DOI

TL;DR

This study identifies phosphoenolpyruvate carboxykinase 1 (PCK1) as a key player in IgA nephropathy (IgAN), a common cause of kidney disease. They found that reduced PCK1 expression in kidney cells is linked to disease severity and that boosting PCK1 levels can protect against inflammation and fibrosis, suggesting PCK1 as a potential therapeutic target.

What Problem Does This Paper Address?

IgA nephropathy (IgAN) is a leading cause of chronic kidney disease (CKD), characterized by the deposition of IgA immune complexes in the glomeruli. While the general mechanisms are understood, the precise molecular pathways driving its progression, particularly inflammation and fibrosis, remain incompletely elucidated. Current treatments focus on general kidney protection and immunosuppression, but there's a need for more targeted therapies. This paper aims to identify novel molecular targets by investigating the role of PCK1, an enzyme involved in various metabolic processes, in the context of IgAN.

Methods

The researchers employed a multi-pronged approach:

  • Bioinformatics Analysis: They used weighted gene co-expression network analysis (WGCNA) on publicly available gene expression datasets (GEO) from IgAN patients and healthy controls to identify differentially expressed genes (DEGs) and key pathways. This involved comparing three datasets (GSE93798, GSE37460, GSE104948) to find common DEGs and then performing Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis.
  • In Vitro Cell Culture Model: They utilized SV40-transformed mouse mesangial cells (MCs), the primary cells affected in IgAN, to create an IgAN disease model by stimulating them with polymeric IgA1 (pIgA1).
  • Experimental Validation:
    • Immunohistochemistry (IHC) and Immunofluorescence (IF): These techniques were used to examine the expression levels of PCK1 and other relevant markers (like PDGFR-β, PPARY, inflammatory cytokines, and fibrosis markers) in both clinical kidney tissue samples and cultured cells.
  • Western Blotting: This was used to quantify protein expression levels of PCK1, PPARY, and various inflammatory and fibrotic markers in cell cultures.
  • qRT-PCR: This method was used to measure mRNA expression levels of inflammatory markers.
  • MTT Assay: Used to assess cell proliferation and determine optimal stimulation conditions for the cell model.
  • Gene Overexpression: Lentivirus vectors were used to overexpress PCK1 in MCs to investigate its protective effects.
  • Drug Treatment: Rosiglitazone, a known PPARY agonist, was used to compare its effects with PCK1 overexpression.

Datasets

The study utilized the following publicly available gene expression datasets from the Gene Expression Omnibus (GEO) database:

  • GSE93798: Used for validation of PCK1 expression and diagnostic accuracy.
  • GSE37460: Used for initial screening of differentially expressed genes (DEGs) and pathway analysis.
  • GSE104948: Used for initial screening of DEGs and pathway analysis.

The study also collected clinical renal tissue samples from 79 patients with IgAN and 30 healthy controls.

Key Insights and Ideas

  • PCK1 as a Downregulated Player: The study consistently found significantly lower PCK1 expression in IgAN kidney tissues compared to healthy controls, across multiple datasets and in clinical samples. This downregulation was also observed in pIgA1-stimulated mesangial cells.
  • PCK1 and PPARY Synergy: PCK1 expression was found to be strongly positively correlated with PPARY expression, suggesting a cooperative role in kidney health. This aligns with PPARY's known protective functions in kidney disease.
  • PCK1's Protective Role: Overexpressing PCK1 in mesangial cells significantly inhibited the expression of inflammatory markers (like MCP-1 and TNF-α) and fibrotic markers (like TGF-β1, p-Smad3, α-SMA, FN, and collagen IV) induced by pIgA1.
  • Rosiglitazone Mimics PCK1's Effects: Treatment with rosiglitazone, a PPARY agonist, also led to increased PCK1 expression and showed similar protective effects against fibrosis as PCK1 overexpression, hinting that PCK1 might be a key mediator of PPARY's benefits.
  • PCK1 as a Diagnostic and Prognostic Marker: The study demonstrated that PCK1 expression levels could serve as a reliable diagnostic marker for IgAN, with high AUC values in ROC curve analyses. Furthermore, lower PCK1 expression correlated with more severe pathological changes and poorer clinical indicators, suggesting its potential as a prognostic marker.

Key Results

  • Differential Gene Expression: Identified 68 DEGs in GSE37460 and 80 DEGs in GSE104948.
  • PCK1 Downregulation: PCK1 expression was significantly decreased in IgAN patients compared to controls (p<0.001 in GSE37460 and GSE104948, p=2.7e-11 in GSE93798).
  • Diagnostic Value of PCK1: ROC curve analysis showed high diagnostic accuracy for PCK1 in IgAN (AUC = 0.859 for GSE37460, 0.877 for GSE104948, and 0.993 for GSE93798).
  • Correlation with Disease Severity: Lower PCK1 expression was associated with more severe pathological subtypes (M1, E1, S1, C1/2) and higher Katafuchi scores (r=-0.396, p<0.01).
  • Correlation with Clinical Indicators: PCK1 expression negatively correlated with 24-h proteinuria (r=-0.927), urine albumin-to-creatinine ratio (r=-0.81), serum creatinine (r=-0.421), and blood urea nitrogen (r=-0.387), and positively correlated with serum albumin (r=0.388) and eGFR (r=0.513).
  • Inhibition of Inflammatory and Fibrotic Markers: PCK1 overexpression significantly reduced the expression of inflammatory cytokines (MCP-1, TNF-α) and fibrosis markers (TGF-β1, p-Smad3, α-SMA, FN, collagen IV) in pIgA1-stimulated MCs.

Limitations and Future Work

  • Animal Model vs. Human Disease: While the study used an in vitro IgAN model, the direct translation of these findings to the complex in vivo human disease requires further investigation.
  • Mechanistic Details: While the study shows PCK1's protective effects, the precise downstream molecular mechanisms by which PCK1 exerts these effects, particularly its interaction with the PPARY pathway, could be further explored.
  • Clinical Validation: Although PCK1 showed diagnostic and prognostic potential, larger-scale prospective clinical studies are needed to fully validate its utility as a biomarker.
  • Therapeutic Development: The study suggests PCK1 as a therapeutic target. Future work could focus on developing specific PCK1 modulators or therapies that enhance its activity for IgAN treatment. The hypothesis that PPARY agonists work through PCK1 upregulation warrants further experimental validation.

Summary updated

Abstract

PCK1 exerted a pronounced inhibitory effect on mesangial cell inflammatory markers and fibrosis indicators in IgAN, potentially offering a novel therapeutic target for its treatment.
BibTeX
@inproceedings{tan2025protective,
  author = {Ying Tan and Yu–Kai Wang and Xiaomei Luo and Chaoyi Chen and Xue‐qi Liu and Xinran Liu and Yonggui Wu},
  title = {{Protective effect of phosphoenolpyruvate carboxykinase 1 on inflammation and fibrotic progression of IgA nephropathy}},
  booktitle = {Renal},
  year = {2025},
  doi = {10.1080/0886022x.2025.2508297},
}
Figure